Similar Search Results

Pharmaceutical innovation : revolutionizing human health

Landau, Ralph (ed.); Achilladelis, Basil (contributor); … - 1999

Persistent link: https://www.econbiz.de/10001423161

Changing innovation in the pharmaceutical industry : globalization and new ways of drug development ; with 28 tables

Jungmittag, Andre (ed.); Reger, Guido (contributor); … - 2000

Persistent link: https://www.econbiz.de/10001480694

The pharmaceutical industry : access and outlook

Parvis, Ethan N. (contributor) - 2002

Persistent link: https://www.econbiz.de/10001659596

Option framework for the valuation of biopharmaceutical companies

Wörner, Stefan - 2001

Persistent link: https://www.econbiz.de/10001640764

The politics of the international pricing of prescription drugs

Harrison, Christopher Scott - 2004 - 1. publ.

Persistent link: https://www.econbiz.de/10001786493

The $800 million pill : the truth behind the cost of new drugs

Goozner, Merrill - 2004

Persistent link: https://www.econbiz.de/10001803092

The truth about the drug companies : how they deceive us and what to do about it

Angell, Marcia - 2004

Persistent link: https://www.econbiz.de/10001870541

Strategies in pharmacoeconomics and outcomes research

Rychlik, Reinhard - 2002

Persistent link: https://www.econbiz.de/10001669610

Evaluating the US pharmaceutical patent policy

Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2021

The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...

Persistent link: https://www.econbiz.de/10012802183

Pharma-Innovationen: Überragende Position der USA und Schwächen der deutschen universitären und außeruniversitären Forschung

Eckert, Andreas; Maennig, Wolfgang - 2021

verwerteten Patenten misst. Nach unseren Berechnungen sind Unternehmen der USA in den Jahren 2010 bis 2019 für mehr als die Hälfte …. 9%. Bei den Ankerpatenten, die diesen Durchbrüchen zugrunde liegen, ist die Dominanz der USA mit 62% sogar noch größer …

Persistent link: https://www.econbiz.de/10012548170